Roivant Sciences Ltd. cotiza a 35.44 USD y tiene una capitalización bursátil de $25.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indicat…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.34 | $-0.32 | $-0.24 |
| Estimado | $-0.30 | $-0.36 | $-0.35 | $-0.31 |
| Sorpresa | — | +5.6% | +8.6% | +22.6% |
| Métrica | ROIV | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -6235.7% | -38.6% | -6197.1% |
| Net Margin | -3629.2% | -33.6% | -3595.6% |
| FCF Margin | -9183.5% | -13.9% | -9169.6% |
| ROE | -6.6% | -40.4% | +33.8% |
| ROA | -5.3% | -32.0% | +26.8% |
| Current Ratio | 18.37 | 2.84 | +15.53 |
| Debt / Equity | — | 0.28 | — |